XML 20 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Cash flow from operating activities    
Net loss $ (878,561) $ (32,413,693)
Adjustments to reconcile net loss to net cash from operating activities:    
Changes in fair value of derivative liabilities (5,925,000) 28,485,585
Loss on debt settlement agreements 70,315 24,697
Stock based compensation 1,309,109 261,805
Changes in operating assets and liabilities:    
Prepaid expenses (42,849) (55,782)
Accounts payable and accrued liabilities 710,720 204,956
Net cash used in operating activities (4,756,266) (3,492,432)
Cash flow from financing activities    
Private placements 3,135,196 2,464,000
Finders’ fee and legal costs on private placements (804,070) (137,986)
Repayment of promissory note (25,000) 0
Repayment of promissory note - related party (23,000) 0
Proceeds from exercise of warrants 6,000,000 7,427,998
Finders' fee on exercise of warrants (516,651) (316,508)
Net cash provided by financing activities 7,766,475 9,437,504
Net increase in cash 3,010,209 5,945,072
Cash, beginning of period 6,576,564 141,944
Cash, end of period 9,586,773 6,087,016
Supplemental disclosure of cash flow information    
Cash paid for interest 0 0
Cash paid for taxes 0 0
Supplemental schedule of non-cash investing and financing activities:    
Reclassification of accrued liability upon issuance of common shares relating to Dr. Glynn Wilson's compensation 191,000 0
Accounts payable settled in common stock 0 24,000
Fair value of issuance of series F and F-1 warrants as inducement in August 2016 5,352,000 0
Fair value of shares issued as inducement on August 10, 2016 4,500,000 0
Reclassification of fair value of derivative liabilities to equity on amendment of warrant agreements 15,465,000 0
Fair value of issuance of warrants in January and March 2015 financing 0 9,313,000
Issuance of additional warrants in May 28, 2015 transaction 0 6,133,000
Reclassification of Derivative Warrant Liabilities to Equity at Exercise Date $ 5,074,000 $ 11,745,000